Home Newsfeeds Watching Uxin; Zacks Small-Cap Research Sets $2.15 Price Valuation

Watching Uxin; Zacks Small-Cap Research Sets $2.15 Price Valuation

Zacks_SCR_Research_10172022_UXIN_Kerr.pdf

byBenzinga Newsdesk

October 17, 2022

1 minute read

Zacks_SCR_Research_10172022_UXIN_Kerr.pdf

BMO Capital Maintains Outperform on Block, Lowers Price Target to $101

By Benzinga Newsdesk

February 27, 8:48 AM

BMO Capital analyst James Fotheringham maintains Block (NYSE:SQ) with a Outperform and lowers the price target from $108 to $101.

Analyst Ratings

UBS Maintains Buy Rating for CymaBay Therapeutics: Here’s What You Need To Know

By Benzinga Insights

September 26, 1:00 PM

UBS has decided to maintain its Buy rating of CymaBay Therapeutics (NASDAQ:CBAY) and raise its price target from…

CBAY

Why iMedia Brands (IMBI) Stock Is Diving

By Henry Khederian

July 7, 9:29 AM

iMedia Brands, Inc. (NASDAQ: IMBI) shares are trading lower by 11.19% to $0.12 Friday morning after the company has been notified by Nasdaq that its common stock and 8.5% Senior Notes due 2026 will be delisted as a result of the company's voluntary

IMBI

Short Report Casts Doubt On Piedmont Lithium’s Ghana Deal, Alleges ‘Textbook’ Corruption

By AJ Fabino

March 8, 12:23 PM

In 2021, Piedmont Lithium Inc (NASDAQ: PLL) acquired an equity interest in Atlantic Lithium (OTC: ALLIF), a London-based junior mining company with a deal that would see Piedmont garnering the ability to earn a 50% ow

ALLIF

Watching Uxin; Zacks Small-Cap Research Sets $2.15 Price Valuation

Related Posts

BMO Capital Maintains Outperform on Block, Lowers Price Target to $101

UBS Maintains Buy Rating for CymaBay Therapeutics: Here’s What You Need To Know

Why iMedia Brands (IMBI) Stock Is Diving

Short Report Casts Doubt On Piedmont Lithium’s Ghana Deal, Alleges ‘Textbook’ Corruption